ACADIA Pharmaceuticals Inc (ACAD)
16.71
+0.40
(+2.45%)
USD |
NASDAQ |
Apr 26, 16:00
16.72
+0.01
(+0.06%)
After-Hours: 20:00
ACADIA Pharmaceuticals Accounts Payable (Quarterly): 17.54M for Dec. 31, 2023
Accounts Payable (Quarterly) Chart
Historical Accounts Payable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 17.54M |
September 30, 2023 | 12.31M |
June 30, 2023 | 18.81M |
March 31, 2023 | 17.42M |
December 31, 2022 | 12.75M |
September 30, 2022 | 10.01M |
June 30, 2022 | 11.85M |
March 31, 2022 | 10.77M |
December 31, 2021 | 6.876M |
September 30, 2021 | 7.722M |
June 30, 2021 | 9.065M |
March 31, 2021 | 8.849M |
December 31, 2020 | 8.493M |
September 30, 2020 | 3.471M |
June 30, 2020 | 6.466M |
March 31, 2020 | 6.623M |
December 31, 2019 | 7.222M |
September 30, 2019 | 3.444M |
June 30, 2019 | 4.65M |
March 31, 2019 | 3.275M |
December 31, 2018 | 3.167M |
September 30, 2018 | 2.955M |
June 30, 2018 | 3.333M |
March 31, 2018 | 2.996M |
December 31, 2017 | 8.786M |
Date | Value |
---|---|
September 30, 2017 | 2.962M |
June 30, 2017 | 3.588M |
March 31, 2017 | 2.166M |
December 31, 2016 | 3.912M |
September 30, 2016 | 2.828M |
June 30, 2016 | 1.024M |
March 31, 2016 | 1.307M |
December 31, 2015 | 1.672M |
September 30, 2015 | 2.204M |
June 30, 2015 | 2.916M |
March 31, 2015 | 2.518M |
December 31, 2014 | 2.016M |
September 30, 2014 | 1.11M |
June 30, 2014 | 1.104M |
March 31, 2014 | 1.562M |
December 31, 2013 | 0.372M |
September 30, 2013 | 1.12M |
June 30, 2013 | 1.177M |
March 31, 2013 | 1.396M |
December 31, 2012 | 1.375M |
September 30, 2012 | 1.131M |
June 30, 2012 | 0.757M |
March 31, 2012 | 1.035M |
December 31, 2011 | 1.96M |
September 30, 2011 | 1.262M |
Accounts Payable Definition
Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.
Accounts Payable (Quarterly) Range, Past 5 Years
3.444M
Minimum
Sep 2019
18.81M
Maximum
Jun 2023
9.702M
Average
8.849M
Median
Mar 2021
Accounts Payable (Quarterly) Benchmarks
Amylyx Pharmaceuticals Inc | 22.06M |
Regulus Therapeutics Inc | 0.204M |
Tonix Pharmaceuticals Holding Corp | 3.782M |
Minerva Neurosciences Inc | 1.805M |
Viking Therapeutics Inc | 5.225M |